Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

07.03.2024 | original article

Significance of plasma relaxin-2 levels in patients with primary hypertension and type 2 diabetes mellitus

verfasst von: Olena Pankova, Oleksii Korzh

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 7-8/2024

Einloggen, um Zugang zu erhalten

Summary

Background

This study aimed to evaluate plasma relaxin‑2 (RLN-2) levels in patients with arterial hypertension (AH) and their relationships with clinical and laboratory parameters.

Methods

The study involved 106 hypertensive patients, including 55 with type 2 diabetes mellitus (T2DM), and 30 control subjects. Plasma RLN-2 levels were measured using an enzyme-linked immunosorbent assay kit.

Results

RLN-2 levels were reduced in patients with AH compared to healthy volunteers (p < 0.001), and hypertensive patients with T2DM had lower RLN-2 levels than those without impaired glucose metabolism (p < 0.001). RLN‑2 was negatively correlated with systolic blood pressure (SBP) (p < 0.001) and anthropometric parameters such as body mass index (BMI; p = 0.027), neck (p = 0.045) and waist (p = 0.003) circumferences, and waist-to-hip ratio (p = 0.011). RLN‑2 also had inverse associations with uric acid levels (p = 0.019) and lipid profile parameters, particularly triglycerides (p < 0.001) and non-HDL-C/HDL‑C (p < 0.001), and a positive relationship with HDL‑C (p < 0.001). RLN‑2 was negatively associated with glucose (p < 0.001), insulin (p = 0.043), HbA1c (p < 0.001), and HOMA-IR index (p < 0.001). Univariate binary logistic regression identified RLN‑2 as a significant predictor of impaired glucose metabolism (p < 0.001).

Conclusions

Decreased RLN-2 levels in patients with AH and T2DM and established relationships of RLN‑2 with SBP and parameters of glucose metabolism and lipid profile suggest a diagnostic role of RLN‑2 as a biomarker for AH with T2DM.
Vorheriger Artikel „Er weiß es noch nicht“ – Triadische Kommunikation und ihre Tücken am Beispiel eines onkologischen Visitengesprächs
Literatur
1.
2.
Ohishi M. Hypertension with diabetes mellitus: physiology and pathology. Hypertens Res. 2018;41(6):389–93.PubMedCrossRef
3.
Bathgate RA, Halls ML, van der Westhuizen ET, et al. Relaxin family peptides and their receptors. Physiol Rev. 2013;93(1):405–80.PubMedCrossRef
4.
Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. Faseb J. 2001;15(12):2187–95.PubMedCrossRef
5.
Aragón-Herrera A, Feijóo-Bandín S, Anido-Varela L, et al. Relaxin‑2 as a Potential Biomarker in Cardiovascular Diseases. J Pers Med. 2022;12(7):1021.PubMedPubMedCentralCrossRef
6.
Feijóo-Bandín S, Aragón-Herrera A, Rodríguez-Penas D, et al. Relaxin‑2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives. Front Physiol. 2017;8:599.PubMedPubMedCentralCrossRef
7.
Hossain MA, Praveen P, Noorzi NA, et al. Development of Novel High-Affinity Antagonists for the Relaxin Family Peptide Receptor 1. Acs Pharmacol Transl Sci. 2023;6(5):842–53.PubMedCrossRef
8.
Lian X, Beer-Hammer S, König GM, et al. RXFP1 Receptor Activation by Relaxin‑2 Induces Vascular Relaxation in Mice via a Gαi2-Protein/PI3Kß/γ/Nitric Oxide-Coupled Pathway. Front Physiol. 2018;9:1234.PubMedPubMedCentralCrossRef
9.
Sasser JM, Cunningham MW Jr, Baylis C. Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Renal Physiol. 2014;307(12):F1355–F62.PubMedPubMedCentralCrossRef
10.
Snowdon VK, Lachlan NJ, Hoy AM, et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Med. 2017;14(2):e1002248.PubMedPubMedCentralCrossRef
11.
Xu Q, Chakravorty A, Bathgate RA, Dart AM, Du XJ. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension. 2010;55(5):1260–6.PubMedCrossRef
12.
Ponikowski P, Mitrovic V, Ruda M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J. 2014;35(7):431–41.PubMedCrossRef
13.
Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin‑2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39.PubMedCrossRef
14.
Metra M, Teerlink JR, Cotter G, et al. Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med. 2019;381(8):716–26.PubMedCrossRef
15.
Corcoran D, Radjenovic A, Mordi IR, et al. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Cardiovasc Res. 2021;117(1):320–9.PubMedCrossRef
16.
Kobalava Z, Villevalde S, Kotovskaya Y, et al. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. Br J Clin Pharmacol. 2015;79(6):937–45.PubMedPubMedCentralCrossRef
17.
Gifford FJ, Dunne PDJ, Weir G, et al. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Trials. 2020;21(1):260.PubMedPubMedCentralCrossRef
18.
Dahlke M, Halabi A, Canadi J, Tsubouchi C, Machineni S, Pang Y. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study. J Clin Pharmacol. 2016;56(4):474–83.PubMedCrossRef
19.
Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(4):1102–11.PubMedPubMedCentralCrossRef
20.
Sonaglia F, Milia P, Caserio M, et al. Efficacy and safety of oral porcine relaxin (pRLX) in adjunct to physical exercise in the treatment of peripheral arterial disease (PAD). Ital J Anat Embryol. 2013;118(1 Suppl):84–91.
21.
Gedikli O, Yilmaz H, Kiris A, et al. Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension. Blood Press. 2009;18(1–2:68–73.CrossRef
22.
Zhang X, Zhu M, Zhao M, et al. The plasma levels of relaxin‑2 and relaxin‑3 in patients with diabetes. Clin Biochem. 2013;46(16–17:1713–6.CrossRef
23.
Szepietowska B, Gorska M, Szelachowska M. Plasma relaxin concentration is related to beta-cell function and insulin sensitivity in women with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;79(3):e1–e3.PubMedCrossRef
24.
Gao X, Li H, Wang P, Chen H. Decreased Serum Relaxin‑2 Is Correlated with Impaired Islet β‑Cell Function in Patients with Unstable Angina and Abnormal Glucose Metabolism. Int Heart J. 2018;59(2):272–8.PubMedCrossRef
25.
Bryant GD, Panter ME, Stelmasiak T. Immunoreactive relaxin in human serum during the menstrual cycle. J Clin Endocrinol Metab. 1975;41(06):1065–9.PubMedCrossRef
26.
Nose-Ogura S, Yoshino O, Yamada-Nomoto K, et al. Oral contraceptive therapy reduces serum relaxin‑2 in elite female athletes. J Obstet Gynaecol Res. 2017;43(3):530–5.PubMedCrossRef
27.
Casey E, Anderson T, Wideman L, et al. Optimal Paradigms for Measuring Peak Serum Relaxin in Eumenorrheic, Active Females. Reprod Med Int. 2018;1:6.
28.
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475]. Eur Heart J. 2018;39(33):3021–104.
29.
American Diabetes Association Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clin. Diabetes. 2022;40(1):10–38.
30.
Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney. Dis Kidney Inter Suppl. 2013;3(1):1–150.
31.
World Health Organization Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.
32.
World Health Organization Physical status: the use and interpretation of anthropometry. Report of a WHO. Ser, Vol. 854. Committee. World Health Organ Tech Rep: Expert; 1995. pp. 1–452.
33.
34.
Bryant GD, Sassin JF, Weitzman ED, et al. Relaxin immunoactivity in human plasma during a 24-hr period. J Reprod Fertil. 1976;48(2):389–92.PubMedCrossRef
35.
Pintalhao M, Castro-Chaves P, Vasques-Novoa F, et al. Relaxin serum levels in acute heart failure are associated with pulmonary hypertension and right heart overload. Eur J Heart Fail. 2017;19(2):218–25.PubMedCrossRef
36.
Kupari M, Mikkola TS, Turto H, et al. Is the pregnancy hormone relaxin an important player in human heart failure? Eur J Heart Fail. 2005;7(2):195–8.PubMedCrossRef
37.
Aragón-Herrera A, Couselo-Seijas M, Feijóo-Bandín S, et al. Relaxin‑2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers. Sci Rep. 2022;12(1:22287.CrossRef
38.
Wolf JM, Cameron KL, Clifton KB, et al. Serum relaxin levels in young athletic men are comparable with those in women. Orthopedics. 2013;36(2):128–31.PubMedCrossRef
39.
Dragoo JL, Castillo TN, Braun HJ, et al. Prospective correlation between serum relaxin concentration and anterior cruciate ligament tears among elite collegiate female athletes. Am J Sports Med. 2011;39(10):2175–80.PubMedCrossRef
40.
Owens BD, Cameron KL, Clifton KB, et al. Association Between Serum Relaxin and Subsequent Shoulder Instability. Orthopedics. 2016;39(4):e724–e8.PubMedCrossRef
41.
Nonhoff J, Ricke-Hoch M, Mueller M, et al. Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovasc Res. 2017;113(6):598–608.PubMedPubMedCentral
42.
Dragoo JL, Castillo TN, Korotkova TA, et al. Trends in serum relaxin concentration among elite collegiate female athletes. Int J Womens Health. 2011;3:19–24.PubMedPubMedCentral
43.
Giordano N, Papakostas P, Lucani B, et al. Serum relaxin in systemic sclerosis. J Rheumatol. 2005;32(11):2164–6.PubMed
44.
Binder C, Simon A, Binder L, et al. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat. 2004;87(2):157–66.PubMedCrossRef
45.
Krüger S, Graf J, Merx MW, et al. Relaxin kinetics during dynamic exercise in patients with chronic heart failure. Eur J Intern Med. 2004;15(1):54–6.PubMedCrossRef
46.
Wolf JM, Scher DL, Etchill EW, et al. Relationship of relaxin hormone and thumb carpometacarpal joint arthritis. Clin Orthop Relat Res. 2014;472(4):1130–7.PubMedCrossRef
47.
Schöndorf T, Lübben G, Hoopmann M, et al. Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. Gynecol Endocrinol. 2007;23(6):356–60.PubMedCrossRef
48.
Samuel CS, Royce SG, Hewitson TD, Denton KM, Cooney TE, Bennett RG. Anti-fibrotic actions of relaxin [published correction appears in Br J Pharmacol. 2017;174(24):4836]. Br J Pharmacol. 2017;174(10):962–976.
49.
Wolf JM, Williams AE, Delaronde S, et al. Relationship of serum relaxin to generalized and trapezial-metacarpal joint laxity. J Hand Surg Am. 2013;38(4):721–8.PubMedCrossRef
50.
Papadopoulos DP, Makris T, Perrea D, et al. Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension. J Clin Hypertens (greenwich). 2014;16(3):198–201.PubMedCrossRef
51.
Papadopoulos DP, Mourouzis I, Faselis C, et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (greenwich). 2013;15(5):333–6.PubMedCrossRef
52.
Sanidas E, Tsakalis K, Papadopoulos DP, et al. The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension. J Clin Hypertens (greenwich). 2019;21(1):48–52.PubMedCrossRef
53.
Bonanno A, Riccobono L, Bonsignore MR, et al. Relaxin in Obstructive Sleep Apnea: Relationship with Blood Pressure and Inflammatory Mediators. Respiration. 2016;91(1):56–62.PubMedCrossRef
54.
Lopez AY, Dereke J, Landin-Olsson M, et al. Plasma levels of relaxin‑2 are higher and correlated to C‑peptide levels in early gestational diabetes mellitus. Endocrine. 2017;57(3):545–7.CrossRef
55.
Wang P, Li HW, Wang YP, Chen H, Zhang P. Effects of recombinant human relaxin upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition. J Endocrinol Invest. 2009;32(3):242–7.PubMedCrossRef
56.
Bonner JS, Lantier L, Hocking KM, et al. Relaxin treatment reverses insulin resistance in mice fed a high-fat diet. Diabetes. 2013;62(9):3251–60.PubMedPubMedCentralCrossRef
57.
Bitto A, Irrera N, Minutoli L, et al. Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice. Clin Sci (lond). 2013;125(12):575–85.PubMedCrossRef
58.
Singh S, Simpson RL, Bennett RG. Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α). J Biol Chem. 2015;290(2):950–9.PubMedCrossRef
59.
Ng HH, Leo CH, Parry LJ, Ritchie RH. Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes. Front Pharmacol. 2018;9:501.PubMedPubMedCentralCrossRef
60.
Ng HH, Leo CH, Prakoso D, Qin C, Ritchie RH, Parry LJ. Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes. Sci Rep. 2017;7:39604.PubMedPubMedCentralCrossRef
61.
Dschietzig TB, Krause-Relle K, Hennequin M, et al. Relaxin‑2 does not ameliorate nephropathy in an experimental model of type‑1 diabetes. Kidney Blood Press Res. 2015;40(1):77–88.PubMedCrossRef
62.
Wong SE, Samuel CS, Kelly DJ, et al. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes. Protein Pept Lett. 2013;20(9):1029–38.PubMedCrossRef
63.
Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786.PubMedPubMedCentralCrossRef
64.
Aragón-Herrera A, Feijóo-Bandín S, Abella V, et al. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue. Pharmacol Res. 2019;144:51–65.PubMedCrossRef
65.
Aragón-Herrera A, Feijóo-Bandín S, Moraña-Fernández S, et al. Relaxin has beneficial effects on liver lipidome and metabolic enzymes. Faseb J. 2021;35(7):e21737.PubMedCrossRef
66.
McGowan BM, Minnion JS, Murphy KG, et al. Central and peripheral administration of human relaxin‑2 to adult male rats inhibits food intake. Diabetes Obes Metab. 2010;12(12):1090–6.PubMedCrossRef
67.
Borghi C, Cicero AFG. Serum Uric Acid and Cardiometabolic Disease: Another Brick in the Wall? Hypertension. 2017;69(6:1011–3.CrossRef
Metadaten
Titel
Significance of plasma relaxin-2 levels in patients with primary hypertension and type 2 diabetes mellitus
verfasst von
Olena Pankova
Oleksii Korzh
Publikationsdatum
07.03.2024
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 7-8/2024
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-024-01035-x

Weitere Artikel der Ausgabe 7-8/2024

„Er weiß es noch nicht“ – Triadische Kommunikation und ihre Tücken am Beispiel eines onkologischen Visitengesprächs

  • Open Access
  • Fallbericht

Multidisciplinary expert group: communication measures to increase vaccine compliance in adults

  • Open Access
  • short communication

Influence of appropriate emergency department utilization and verbal communication on physicians’ (dis)satisfaction with doctor–patient interactions with special consideration of migrational backgrounds

  • Open Access
  • original article

Preoperative anxiety after face-to-face patient assessment versus preanaesthesia telemedicine (PANTEM) in adults: a randomised clinical trial

  • original article